5.175
Schlusskurs vom Vortag:
$5.38
Offen:
$5.36
24-Stunden-Volumen:
95,398
Relative Volume:
0.31
Marktkapitalisierung:
$137.32M
Einnahmen:
$59.07M
Nettoeinkommen (Verlust:
$-52.66M
KGV:
-2.5746
EPS:
-2.01
Netto-Cashflow:
$-40.16M
1W Leistung:
+9.18%
1M Leistung:
+0.68%
6M Leistung:
-24.45%
1J Leistung:
-34.99%
Cvrx Inc Stock (CVRX) Company Profile
Firmenname
Cvrx Inc
Sektor
Branche
Telefon
(763) 416-2850
Adresse
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
CVRX
Cvrx Inc
|
5.175 | 129.50M | 59.07M | -52.66M | -40.16M | -2.01 |
|
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-01-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-09-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-11 | Bestätigt | Lake Street | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2024-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Lake Street | Buy |
| 2022-07-18 | Eingeleitet | Craig Hallum | Buy |
| 2021-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-26 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cvrx Inc Aktie (CVRX) Neueste Nachrichten
CVRx to Present at Canaccord Genuity’s 46th Annual Growth Conference - Quiver Quantitative
CVRx presentation will stream live from Boston on Aug. 11 - Stock Titan
CVRX|CVRx Inc|Price:4.870|Chg%:+0.130 - TradingKey
CVRx Inc (CVRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CVRx Inc (CVRX) Balance Sheet - TradingKey
CVRx Inc (CVRX) Institutional Confidence - TradingKey
CVRx Inc (CVRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CVRx Inc (CVRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CVRX|CVRx Inc|Price:4.740|Chg%:-0.150 - TradingKey
CVRx Inc (CVRX) Cash Flow - TradingKey
CVRX|CVRx Inc|Price:4.815|Chg%:+0.075 - TradingKey
CVRx Inc (CVRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CVRx (CVRX) Q4 2025 earnings summary - Quartr
CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026 - The Manila Times
CVRx Plans Aug. 6 Webcast on Second-Quarter Results - Stock Titan
CVRx Inc (CVRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CVRx (CVRX) Proxy filing Summary - Quartr
CVRx partners with Piedmont Columbus Regional Medical Center for first Barostim implant - Traders Union
CVRx (CVRX) The 44th Annual William Blair Growth Stock Conference Summary - Quartr
CVRx (CVRX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary - Quartr
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating - 富途牛牛
CVRx Inc (CVRX) Stock Forum and Discussion - Moomoo
(CVRX) Risk Channels and Responsive Allocation - Stock Traders Daily
CVRx Inc(CVRX) Stock Options Chain | Quotes & News - Moomoo
CVRX Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Cleveland Clinic Florida adopts Barostim implant in collaboration with CVRx - Traders Union
CVRx Inc focuses on heart failure devices as investors watch Nasdaq listing - Ad-hoc-news.de
CVRx (CVRX) Piper Sandler 36th Annual Healthcare Conference Summary - Quartr
CVRx enables first commercial Barostim implant in Washington state for heart failure treatment - Traders Union
CVRx Inc focuses on cardiovascular innovation amid thin market signals - Ad Hoc News
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and CVRx (CVRX) - The Globe and Mail
CVRX Q1 2026 Earnings: EPS Beats Estimates as Loss NarrowsRevenue Breakdown Analysis - dars.gov.et
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Enterprise value to EBIT forward of CVRx, Inc. – NASDAQ:CVRX - TradingView
CVRX,INVA Volatility & Greeks - Finviz
CVRx shares rise on CMS inclusion for Barostim implant procedure - MSN
CVRx (CVRX) moves 11.6% higher: Will this strength last? - MSN
CVRX Q1 2026 Earnings: EPS Exceeds Estimates as Company Navigates Market ChallengesMid-Term Outlook - dars.gov.et
CVRx Inc. (CVRX) Sinks 13.5% as Selling Pressure Intensifies Near Key SupportKeltner Channel - dars.gov.et
CVRX Q1 2026 Earnings: EPS Beats Estimates Amid Operational ProgressEarnings Manipulation Risk - dars.gov.et
CVRx (CVRX) Moves 11.6% Higher: Will This Strength Last? - Yahoo Finance
CVRx Inc. Surges on Strong Trading Activity; Key Resistance Levels AheadTriple Bottom - dars.gov.et
Price to earnings forward of CVRx, Inc. – NASDAQ:CVRX - TradingView
Enterprise value to revenue forward of CVRx, Inc. – NASDAQ:CVRX - TradingView
Price to book forward of CVRx, Inc. – NASDAQ:CVRX - TradingView
CVRx, Inc. Actuals & Estimates (NASDAQ:CVRX) - TradingView
CVRX Forecast — Price Target — Prediction for 2027 - TradingView
(CVRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
CVRx stock up on Humana's Medicare coverage for Barostim therapy - MSN
CVRx Inc (CVRX) Stock Forecast & Analyst Ratings - Moomoo
CVRX Q1 2026 Earnings: EPS Beats Estimates as Pre‑Revenue Progress Drives Stock HigherEarnings Quality Analysis - dars.gov.et
Finanzdaten der Cvrx Inc-Aktie (CVRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cvrx Inc-Aktie (CVRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hykes Kevin | PRES & CEO |
Mar 02 '26 |
Sale |
7.90 |
7,763 |
61,349 |
284,237 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,284 |
10,146 |
60,551 |
| OASHEIM JARED | CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,744 |
13,781 |
96,703 |
| John Robert Allen | Chief Revenue Officer |
Mar 02 '26 |
Sale |
7.90 |
3,964 |
31,326 |
86,036 |
| Jain Mudit K. | Director |
Feb 20 '26 |
Buy |
6.36 |
46,800 |
297,592 |
980,183 |
| Jain Mudit K. | Director |
Feb 18 '26 |
Buy |
4.64 |
600 |
2,785 |
5,650 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 26 '25 |
Sale |
10.03 |
6,337 |
63,560 |
4,040,861 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 21 '25 |
Sale |
10.00 |
500 |
5,000 |
4,049,398 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 12 '25 |
Sale |
10.00 |
1,000 |
10,000 |
4,049,898 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):